Payment overview · 2025
General Payments
$205.85
10 reported records · 6 companies
Healthcare provider profile · identity verified
James C Razi, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LIVE OAK, FL · NPI 1902874233
Verified facts
What the public records show
CMS Open Payments records show James C Razi, M.D. received $205.85 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 29.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ubrelvy by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.64 | 29.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $42.01 | 20.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.86 | 16.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.42 | 12.3% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $24.93 | 12.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.99 | 9.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $205.85 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $59.64 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $59.64 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $42.01 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.42 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 49 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 87 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 26 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 444 | 158 |
| Atorvastatin Calcium | Atorvastatin Calcium | 442 | 170 |
| Gabapentin | Gabapentin | 340 | 113 |
| Lisinopril | Lisinopril | 310 | 117 |
| Omeprazole | Omeprazole | 272 | 99 |
| Alprazolam | Alprazolam | 239 | 39 |
| Metformin Hcl | Metformin Hcl | 218 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 211 | 87 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 190 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 185 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 173 | 58 |
| Losartan Potassium | Losartan Potassium | 160 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 51 |
| Tramadol Hcl | Tramadol Hcl | 146 | 47 |
| Trazodone Hcl | Trazodone Hcl | 144 | 51 |
| Sertraline Hcl | Sertraline Hcl | 134 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 129 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 43 |
| Meloxicam | Meloxicam | 119 | 38 |
| Naproxen | Naproxen | 118 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 47 |
| Montelukast Sodium | Montelukast Sodium | 114 | 41 |
| Furosemide | Furosemide | 111 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 108 | 38 |
| Carvedilol | Carvedilol | 105 | 49 |
| Simvastatin | Simvastatin | 93 | 29 |
| Methylprednisolone | Methylprednisolone | 92 | 72 |
| Eliquis | Apixaban | 89 | 31 |
| Potassium Chloride | Potassium Chloride | 88 | 38 |
| Ozempic | Semaglutide | 87 | 26 |
| Glipizide | Glipizide | 84 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 33 |
| Pregabalin | Pregabalin | 75 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 30 |
| Celecoxib | Celecoxib | 66 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 30 |
| Doxepin Hcl | Doxepin Hcl | 66 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 20 |
| Famotidine | Famotidine | 64 | 25 |
| Allopurinol | Allopurinol | 63 | 22 |
| Buspirone Hcl | Buspirone Hcl | 63 | 20 |
| Ibuprofen | Ibuprofen | 62 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 17 |
| Meclizine Hcl | Meclizine Hcl | 56 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 17 |
| Baclofen | Baclofen | 55 | 20 |
| Farxiga | Dapagliflozin Propanediol | 53 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 13 |
| Topiramate | Topiramate | 51 | 17 |
| Ezetimibe | Ezetimibe | 50 | 18 |
| Clonazepam | Clonazepam | 49 | suppressed |
| Jardiance | Empagliflozin | 49 | 17 |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Lorazepam | Lorazepam | 47 | 11 |
| Azithromycin | Azithromycin | 45 | 41 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 24 |
| Januvia | Sitagliptin Phosphate | 44 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | suppressed |
| Atenolol | Atenolol | 42 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 12 |
| Methocarbamol | Methocarbamol | 37 | 14 |
| Temazepam | Temazepam | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | 13 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 18 |
| Lovastatin | Lovastatin | 32 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 32 | 11 |
| Prednisone | Prednisone | 31 | 23 |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | 11 |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | 15 |
| Diazepam | Diazepam | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 25 |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 24 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 16 |
| Glimepiride | Glimepiride | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | 12 |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | 11 |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | 15 |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Nystatin | Nystatin | 19 | 12 |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | 13 |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 16 |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $205.85 · 10 records | ABBVIE INC. | CAPLYTA, JARDIANCE, MOUNJARO, Ozempic, QULIPTA, Rybelsus, TZIELD, UBRELVY, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error